CRISPR Patent Ruling May Push Warring Sides To A Deal
By Ryan Davis (September 11, 2018, 10:09 PM EDT) -- The Federal Circuit's decision Monday rejecting the University of California's efforts to secure control over patents on the breakthrough gene-editing system CRISPR in a fight with the Broad Institute leaves an unsettled patent landscape for the technology that could spur the parties to strike a deal, attorneys say.
The appeals court upheld a Patent Trial and Appeal Board ruling that found no overlap between patents sought by UC covering the use of CRISPR in any environment and those issued to Broad that cover its use in plant and animal cells. While UC maintained it invented the technology first and was entitled...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!